2025 MLS Nashville | Colorectal Cancer Updates in 2025
Overview
Dr. Eng noted that while challenges persist in colorectal cancer, MSI‑high patients in Atezo‑ATOMIC achieved superior 3‑year DFS with oxaliplatin/fluorouracil + atezolizumab (86.4 % vs 76.6 %), and BRAF V600E patients in BREAKWATER saw markedly longer PFS and a 30.3‑month median OS on encorafenib + cetuximab + FOLFOX. Conversely, the DYNAMIC‑3 study showed that using circulating tumor DNA to guide adjuvant therapy conferred no benefit.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Cathy Eng, MD
Date of Release
June 25th, 2025
